Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from I-MAB ( (IMAB) ) is now available.
On June 2, 2025, I-Mab announced the advancement of its potential best-in-class CLDN18.2 therapeutic, givastomig, for gastric cancer. The company has fully enrolled a Phase 1b escalation study of givastomig in combination with nivolumab and chemotherapy, with topline data to be presented at the ESMO GI 2025. This development positions I-Mab to potentially capture a share of the $12 billion global market for metastatic gastric cancer, with further expansion into other tumor types. The company maintains a strong capital position with $168.6 million in cash, providing financial runway into 2027, supporting its clinical readouts and operational goals.
The most recent analyst rating on (IMAB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.
Spark’s Take on IMAB Stock
According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.
The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
To see Spark’s full report on IMAB stock, click here.
More about I-MAB
I-Mab is a biopharmaceutical company focused on the development of innovative therapies for cancer treatment. The company specializes in creating novel bispecific antibodies and monoclonal antibodies targeting various cancer indications, with a significant emphasis on gastric cancer, pancreatic ductal adenocarcinoma, and cholangiocarcinoma. I-Mab operates with a capital-efficient model and a U.S.-based management team, aiming to advance its pipeline through strategic collaborations and partnerships.
Average Trading Volume: 231,950
Technical Sentiment Signal: Sell
Current Market Cap: $103.4M
Find detailed analytics on IMAB stock on TipRanks’ Stock Analysis page.